Perrigo bolsters generics portfolio with Paddock acquisition
This article was originally published in Scrip
Executive Summary
Perrigo is expanding its generics portfolio by paying $540 million in cash for substantially all of the assets of Paddock Laboratories, a privately-held manufacturer and marketer of generic pharmaceuticals based in Minneapolis, US.